“STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more”

Key points

• Four major drugmakers paid tens of millions to proxies in Russia between 2020 and 2023.
• Investigation reports allege excessive bonuses to R-Pharm and other intermediaries.
• Middlemen faced scrutiny for bid rigging or anticompetitive conduct in Russia.
• KYmera Therapeutics is poised to reveal mid-stage eczema data for KT-621.
• Analysts call Kymera results potentially game-changing for immunology and inflammation.